Lanthio

11 May / 2015

May 11, 2015 / 12:00 pm, CEST

INKEF Capital Portfolio Company Lanthio Pharma Acquired by MorphoSys

Amsterdam – On May 7th, MorphoSys AG approved the acquisition of all outstanding shares of the Dutch biopharmaceutical company Lanthio Pharma B.V for € 20 million. The transaction centers on Lanthio Pharma’s lead compound LP2, a novel lanthipeptide in development for diabetic nephropathy and fibrotic diseases, that is part of a broader pipeline of lanthipeptide products.

INKEF made its initial equity investment in November 2012 as part of Lanthio Pharma’s Series A financing round, which also included investment by MorphoSys’ Innovation Capital initiative, BioGeneration Ventures and Hanzepoort. Since, INKEF has been the largest shareholder in Lanthio Pharma working closely with management to further define the business and development strategy and ultimately negotiating the acquisition agreement with MorphoSys.

“We want to congratulate the founders, the management and all employees of Lanthio Pharma. Their creativity and entrepreneurial spirit enabled Lanthio Pharma to become a very promising biotech company and this was clearly recognized by MorphoSys.” noted Dirk Kersten, Managing Director of INKEF. “We would like to thank MorphoSys for their strong support during the past years. We look forward to continue working with MorphoSys and its Innovation Capital initiative.”

“We are pleased with the successful acquisition of Lanthio Pharma,” added Jens Holstein, CFO of MorphoSys AG. “We would like to thank the team of INKEF for the trustful collaboration over the last years and are looking forward to collaborating in other exciting ventures in the future.”

“We are very happy about this transaction and believe that MorphoSys´ outstanding capabilities will give our product candidates and technology an excellent opportunity to realize their full potential. The acquisition also represents a successful exit for our investors of which in particular INKEF played a crucial role for this success.”, commented Dr. Heinz Schwer, Chief Executive Officer of Lanthio Pharma on the collaboration with INKEF.

The acquisition of Lanthio Pharma represents the third successful exit for INKEF in the past 24 months. Prior acquisitions include ProFibrix (acquired by The Medicines Company) and Sapiens Steering Brain Stimulation (acquired by Medtronic).

About INKEF:

INKEF is a venture capital firm that is focused on the long-term collaboration and active support of innovative technology companies. INKEF was founded in 2010 and with € 200 million under management represents one of the largest venture capital funds in the Netherlands. Since its founding, INKEF has completed nine investments and continues to build out its portfolio in the healthcare and technology sectors.

 

For further information:

 Dirk Kersten

INKEF Capital B.V.
 Gustav Mahlerplein 3 – 27th Floor 1082 MS  Amsterdam
 Tel: +31 20 7946060

Email: dirk.kersten@inkefcapital.com www.inkefcapital.com